Clarkston Capital Partners LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 248,961 shares of the company’s stock after selling 3,220 shares during the period. Clarkston Capital Partners LLC’s holdings in Johnson & Johnson were worth $32,128,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in JNJ. Fundsmith Equity Fund L.P. bought a new position in shares of Johnson & Johnson in the second quarter valued at $552,762,000. Vanguard Group Inc grew its stake in shares of Johnson & Johnson by 1.5% in the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.5% in the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after buying an additional 3,235,861 shares in the last quarter. Morgan Stanley grew its stake in shares of Johnson & Johnson by 6.3% in the third quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock valued at $3,166,921,000 after buying an additional 1,352,484 shares in the last quarter. Finally, Royal London Asset Management Ltd. bought a new position in Johnson & Johnson during the second quarter worth $150,576,000. 67.29% of the stock is owned by institutional investors and hedge funds.
JNJ stock opened at $136.52 on Tuesday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The firm has a market cap of $362.76 billion, a price-to-earnings ratio of 16.69, a P/E/G ratio of 2.07 and a beta of 0.68.
Johnson & Johnson announced that its board has authorized a share buyback program on Monday, December 17th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to reacquire up to 1.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.
A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective for the company in a research report on Wednesday, March 27th. Citigroup lifted their price objective on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Barclays reaffirmed an “equal weight” rating and set a $135.00 price objective (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 2nd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $143.58.
TRADEMARK VIOLATION WARNING: “Clarkston Capital Partners LLC Has $32.13 Million Position in Johnson & Johnson (JNJ)” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2019/04/16/clarkston-capital-partners-llc-has-32-13-million-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Why are gap-down stocks important?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.